Cargando…

P19-36. Preclinical study of CombiHIVvac vaccine

Detalles Bibliográficos
Autores principales:	Kaplina, O, Karpenko, L, Danilenko, E, Bogrjanseva, M, Ilyichev, A
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2767866/ http://dx.doi.org/10.1186/1742-4690-6-S3-P356

Ejemplares similares

Visualization of CombiHIVvac Vaccine Particles Using Electron Microscopy
por: Karpenko, Larisa I., et al.
Publicado: (2017)

P19-13. Recombinant proteins carrying peptide mimics of HIV-1
por: Chikaev, A, et al.
Publicado: (2009)

P19-04. A synergistic effect of a combined bivalent DNA-protein anti-HIV-1 vaccine containing multiple T- and B-cell epitopes of HIV-1 proteins
por: Ilyichev, A, et al.
Publicado: (2009)

Attenuated Salmonella enteritidis E23 as a vehicle for the rectal delivery of DNA vaccine coding for HIV‐1 polyepitope CTL immunogen
por: Karpenko, Larisa I., et al.
Publicado: (2012)

P05-02. Including peptides-mimotopes of neutralizing 2F5 epitope of HIV-1 into artificial peptide TBI – vaccine candidate
por: Scherbakova, NS, et al.
Publicado: (2009)

Consultor Combi visual
Publicado: (1992)

Consultor Combi visual
Publicado: (1988)

Enciclopedia Combi visual
Publicado: (1976)

P36 Consent for Orthopaedic Trauma Surgery during the COVID-19 Pandemic
por: Walker, J, et al.
Publicado: (2021)

The development of the BK-SE36 malaria vaccine candidate
por: Palacpac, Nirianne MQ, et al.
Publicado: (2014)

P04.36. Abstract withdrawn from publication
Publicado: (2012)

P16-36. Functional genomic immune profile of SIV DNA vaccines delivered by electroporation and combined with molecular adjuvants
por: Boyer, JD, et al.
Publicado: (2009)

P17-26. Effective design of T-cell driven vaccines applied to the GAIA HIV vaccine: advances in vaccine design based on current preclinical success
por: De Groot, AS, et al.
Publicado: (2009)

Beam-beam interactions with COMBI
por: Van Daalen, Tal
Publicado: (2015)

P11-02. In situ analysis by confocal microscopy of the cellular components of mucosal tissues within the framework of preclinical vaccine studies
por: Boggiano, CA, et al.
Publicado: (2009)

P-8 Preclinical Cardiac Involvement In Progressive External Ophthalmoplegia
por: Franzoni, F., et al.
Publicado: (2011)

In silico Designed Ebola Virus T-Cell Multi-Epitope DNA Vaccine Constructions Are Immunogenic in Mice
por: Bazhan, Sergei I., et al.
Publicado: (2019)

36. All headaches are not GCA
por: Jain, Nibha, et al.
Publicado: (2019)

P02.36. Meditation or exercise for preventing acute respiratory infection: a randomized controlled trial
por: Barrett, B, et al.
Publicado: (2012)

P01.36. Assessment of commercial formulations of mucuna pruriens seeds for Levodopa (L-DOPA) content
por: Soumyanath, A, et al.
Publicado: (2012)

P05.36. How do lay people conceptualise and reason about the use of placebos in healthcare?
por: Bishop, F, et al.
Publicado: (2012)

Preclinical testing of a novel personalized cancer vaccine for all solid tumors and all patients
por: Jackson, Doreen, et al.
Publicado: (2015)

P04-36. HIV-1-speficic antibody dependant cellular cytotoxicity (ADCC) médiated by primary NK cells
por: Delaporte, M, et al.
Publicado: (2009)

Preclinical animal models of COPD
por: Vlahos, Ross
Publicado: (2013)

P16-45. High avidity CD4+ T cell response directed to an immunodominant Gag epitope in HIV controllers: an ANRS EP36 study
por: Vingert, B, et al.
Publicado: (2009)

PA01.36. Yava- A boon for medoroga
por: Chinnam, Hema Sundari, et al.
Publicado: (2012)

P-147: COVID-19, impact of vaccination in myeloma patients
por: Hoornaert, Ellen, et al.
Publicado: (2021)

Artificial Anti-HIV-1 Immunogen Comprising Epitopes of Broadly Neutralizing Antibodies 2F5, 10E8, and a Peptide Mimic of VRC01 Discontinuous Epitope
por: Rudometov, Andrey P., et al.
Publicado: (2019)

The Structural and Immunological Properties of Chimeric Proteins Containing HIV-1 MPER Sites
por: Rudometov, A. P., et al.
Publicado: (2019)

CombiANT: Antibiotic interaction testing made easy
por: Fatsis-Kavalopoulos, Nikos, et al.
Publicado: (2020)

P19-15. Synthesis of multivalent mimotopes as potential vaccine candidates
por: Go, JG, et al.
Publicado: (2009)

P19-24. Evaluation of recombinant influenza-SIV vaccines in macaques
por: Stambas, J, et al.
Publicado: (2009)

P19-19. MVA vaccines are efficiently cross-presented by DCs and do not enhance HIV replication in DC/T cell cultures
por: Brandler, S, et al.
Publicado: (2009)

A retrospective cohort study of 36-month use of paediatric intensive care and associated mortality in Sweden
por: Kalzen, H, et al.
Publicado: (2005)

Lentiviral-based anti-HIV therapeutic vaccine: design, preclinical studies and phaseI/II clinical trial preliminary results
por: Bauche, Cécile, et al.
Publicado: (2014)

P131: REAL-TIME VACCINATION IMPACTS IN SICKLE CELL DISEASE: A REAL-WORLD PATIENT CASE STUDY FOR INFLUENZA AND COVID-19 VACCINATION
por: Agrippa, O, et al.
Publicado: (2022)

Cyclophosphamide mechanism of action in preclinical tecemotide studies
por: Hance, Ken, et al.
Publicado: (2013)

Lost in translation? Bridging the preclinical / clinical divide
por: Baker, Mark, et al.
Publicado: (2012)

CD36 gene variants and their potential in determining T2DM susceptibility
por: Banerjee, Monisha, et al.
Publicado: (2014)

P19-30. GTU(® )as beneficial HIV DNA vaccine vector system
por: Männik, A, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_7l4r3av040icp8svdkb7l51oeb